ABSTRACT: Estrogens can be converted to electrophilic metabolites, particularly the catechol estrogen-3,4-quinones, estrone(estradiol)-3,4-quinone [E 1 (E 2 )-3,4-Q], which react with DNA to form depurinating adducts. These adducts are released from DNA to generate apurinic sites. Error-prone repair of this damage leads to the mutations that initiate breast, prostate, and other types of cancer. The reaction of E 1 (E 2 )-3,4-Q with DNA forms the depurinating adducts 4-hydroxyE 1 (E 2 )-1-N3adenine [4-OHE 1 (E 2 )-1-N3Ade] and 4-OHE 1 (E 2 )-1-N7guanine(Gua). These two adducts constitute >99% of the total DNA adducts formed. The E 1 (E 2 )-2,3-Q forms small amounts of the depurinating 2-OHE 1 (E 2 )-6-N3Ade adducts. Reaction of the quinones with DNA occurs more abundantly when estrogen metabolism is unbalanced. Such an imbalance is the result of overexpression of estrogen-activating enzymes and/or deficient expression of deactivating (protective) enzymes. Excessive formation of E 1 (E 2 )-3,4-Q is the result of this imbalance. Oxidation of catechols to semiquinones and quinones is a mechanism of tumor initiation not only for endogenous estrogens, but also for synthetic estrogens such as hexestrol and diethylstilbestrol, a human carcinogen. This mechanism is also involved in the initiation of leukemia by benzene, rat olfactory tumors by naphthalene, and neurodegenerative diseases such as Parkinson's disease by dopamine. In fact, dopamine quinone reacts with DNA similarly to the E 1 (E 2 )-3,4-Q, forming analogous depurinating N3Ade and N7Gua adducts. The depurinating adducts that migrate from cells and can be found in body fluids can also serve as biomarkers of cancer risk. In fact, a higher level of estrogen-DNA adducts has been found in the urine of men with prostate cancer and in women with breast cancer compared to healthy controls. This unifying mechanism of the origin of cancer and other diseases suggests preventive
strategies based on the level of depurinating DNA adducts that generate the first critical step in the initiation of diseases.
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ESTROGENS AND CANCER
One of the major obstacles to the advancement of cancer research is related to cancer's being defined as a problem of 200 diseases. This concept has hindered researchers from examining the etiology of cancer because the study would be extremely complex. The above definition is dictated by the different ways in which various types of cancer are expressed. Thus, the etiology of breast, prostate, and other kinds of cancer in humans is still virtually unknown.
A second obstacle to progress in cancer research is related to the reluctance of the scientific community to recognize that natural estrogens, estrone (E 1 ), estradiol (E 2 ), and their specific metabolites, are true carcinogens that induce tumors in hormone-dependent and -independent organs. [1] [2] [3] [4] A third obstacle is related to the initial failure to demonstrate that estrogens induce mutations in bacterial and mammalian systems, 2, [5] [6] [7] [8] [9] resulting in the classification of E 1 and E 2 as epigenetic carcinogens that function mainly by stimulating abnormal cell proliferation via estrogen receptor-mediated processes. 6, [10] [11] [12] [13] [14] The stimulated cell proliferation would result in more opportunities for genetic damage leading to carcinogenesis. 10, 14, 15 There is widespread agreement in the scientific community that cancer is basically a genetic disease, not in the sense that most cancers are inherited (they are not), but in the sense that cancer is triggered by genetic mutations. Thus, cancer can be considered a disease of mutated critical regulatory genes, resulting in abnormal DNA repair and replication, cell proliferation, differentiation and cell death. 16 Exposure to estrogens has been strongly associated in epidemiological studies with an increase in breast cancer risk, with evidence of a dose-response relationship. 17, 18 Induction of prostate adenocarcinomas in 100% of Noble rats implanted with E 2 plus testosterone compared to 40% of rats implanted only with testosterone led to the hypothesis that E 2 initiates and testosterone promotes the development of prostate tumors (see below).
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GENOTOXICITY OF ESTROGENS
Substantial evidence has resulted in a novel paradigm for the initiation of cancer. Discovery that specific oxidative metabolites of estrogens can react with DNA led to the hypothesis that ultimately estrogen metabolites can become endogenous chemical carcinogens by generating the mutations that result in the initiation of cancer (FIG. 1) . [20] [21] [22] [23] [24] [25] [26] [27] [28] Catechol estrogens are among the major metabolites of E 1 and E 2 . If these metabolites are oxidized to the electrophilic catechol estrogen quinones, the latter may react with DNA. Specifically, the carcinogenic 4-hydroxyE 1 (E 2 ) [4-OHE 1 (E 2 )] 2-4 are oxidized to E 1 (E 2 )-3,4-quinones [E 1 (E 2 )-3,4-Q], which react with DNA to form the depurinating adducts 4-OHE 1 (E 2 )-1-N3Ade and 4-OHE 1 (E 2 )-1-N7Gua. 20, 22, 25 The depurination of these adducts generates apurinic sites in the DNA. Error-prone base excision repair of these apurinic sites may lead to cancer-initiating mutations [26] [27] [28] that transform cells, [29] [30] [31] [32] thereby initiating breast, prostate, and other types of human cancer (FIG. 1) . The borderline carcinogenic 2-OHE 2 4 is oxidized to E 2 -2,3-Q, which also forms depurinating DNA adducts, but to a much lesser extent than E 2 -3,4-Q. 23 This initiating mechanism can occur in both hormone-dependent and -independent tissues. Elimination of the initiating step should enable us to prevent a variety of human cancers, including those of the breast and prostate.
METABOLISM OF ESTROGENS AND FORMATION OF
ESTROGEN-DNA ADDUCTS E 1 and E 2 are obtained by aromatization of androstenedione and testosterone, respectively, catalyzed by cytochrome P450 (CYP) 19, aromatase. E 1 and E 2 are biochemically interconvertible by the enzyme 17␤-estradiol dehydrogenase. They are metabolized by two major pathways: formation of catechol estrogens and 16␣-hydroxylation. The catechol estrogens formed are the 2-OHE 1 (E 2 ) and 4-OHE 1 (E 2 ). These two catechol estrogens are generally inactivated by conjugating reactions such as glucuronidation and sulfation, especially in the liver. The most common pathway of conjugation in extrahepatic tissues occurs, however, by O-methylation catalyzed by the ubiquitous catechol-O-methyltransferase (COMT), 33 as shown for 4-OHE 1 (E 2 ) in FIGURE 2.
The level and/or induction of CYP1B1 and other 4-hydroxylases could render 4-OHE 1 (E 2 ) as one of the major catechol estrogens. If conjugation of 4-OHE 1 (E 2 ) via methylation in extrahepatic tissues becomes insufficient, the competitive catalytic oxidation of 4-OHE 1 (E 2 ) to E 1 (E 2 )-3,4-Q can increase (FIG. 2) .
Redox cycling generated by reduction of E 1 (E 2 )-3,4-Q to the semiquinones, catalyzed by CYP reductase, and subsequent oxidation back to E 1 (E 2 )-3,4-Q by O 2 generates superoxide anion radicals and subsequently H 2 O 2 (FIG. 2) . In the presence of Fe 2+ , H 2 O 2 generates hydroxyl radicals. In turn, hydroxyl radicals can produce lipid hydroperoxides. 34, 35 In contrast to NADPH, the lipid hydroperoxides can act as unregulated cofactors of CYP, which give rise to an abnormal increase in the oxidation of 4-OHE 1 (E 2 ) to E 1 (E 2 )-3,4-Q. This can represent one of the major contributions to the formation of E 1 (E 2 )-3,4-Q, which are the ultimate carcinogenic metabolites of estrogens.
The 4-OHE 1 (E 2 ) have greater carcinogenic potency than the 2-OHE 1 (E 2 ).
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It is difficult to attribute the greater potency of 4-OHE 1 (E 2 ) to the formation of hydroxyl radicals obtained by redox cycling of E 1 (E 2 )-3,4-semiquinones and E 1 (E 2 )-3,4-Q, because 2-OHE 1 (E 2 ) and 4-OHE 1 (E 2 ) have similar redox potentials. 36, 37 Instead, one can relate the greater carcinogenic potency of the 4-OHE 1 (E 2 ) to the much higher levels of depurinating DNA adducts formed by E 1 (E 2 )-3,4-Q compared to E 1 (E 2 )-2,3-Q (FIG. 3) . 23 In summary, we think that cancer initiation by E 1 (E 2 )-3,4-Q occurs via formation of depurinating DNA adducts in which the role of hydroxyl radicals is related to increased formation of E 1 (E 2 )-3,4-Q. In fact, formation of lipid hydroperoxides, the unregulated cofactors of CYPs, by hydroxyl radicals renders oxidative stress more severe. E 1 (E 2 )-3,4-Q can be neutralized by conjugation with glutathione (GSH, FIG. 2). A second inactivation pathway for E 1 (E 2 )-3,4-Q is their reduction to 4-OHE 1 (E 2 ) by quinone reductase and/or CYP reductase. 38, 39 If these two inactivating processes are insufficient, E 1 (E 2 )-3,4-Q may react with DNA to form predominantly the depurinating adducts 4-OHE 1 (E 2 )-1-N3Ade and 4-OHE 1 (E 2 )-1-N7Gua.
IMBALANCES IN ESTROGEN HOMEOSTASIS
Cancer initiation by estrogens is based on estrogen metabolism that involves a disrupted homeostatic balance between activating and deactivating pathways. Several factors can unbalance estrogen homeostasis, namely the equilibrium between estrogen-activating and -deactivating pathways with the scope of averting oxidation of catechol estrogens to quinones and their reaction with DNA. These factors include higher levels of 4-OHE 1 (E 2 ) due to overexpression of CYP1B1, which converts E 1 (E 2 ) predominantly to 4-OHE 1 (E 2 ) (FIG. 2) . 40, 41 This could result in relatively large amounts of 4-OHE 1 (E 2 ) and, subsequently, more extensive oxidation to their E 1 (E 2 )-3,4-Q. A second factor could be a low level or lack of COMT activity due to polymorphic variations. If this enzyme activity is insufficient, 4-OHE 1 (E 2 ) will not be effectively methylated, but could be oxidized to the ultimate metabolite E 1 (E 2 )-3,4-Q (FIG. 2) . Third, the formation of lipid hydroperoxides by hydroxyl radicals, generated by redox cycling of 4-OHE 1 (E 2 ), semiquinones and E 1 (E 2 )-3,4-Q (FIG. 2) , can produce an imbalance because lipid hydroperoxides, which are unregulated cofactors in the oxidation of estrogens to 4-OHE 1 (E 2 ) and 4-OHE 1 (E 2 ) to their semiquinones and quinones, can substitute for NADPH. This generates a progressive oxidative stress that results in excessive production of E 1 (E 2 )-3,4-Q. Fourth, a low level of GSH and/or low levels of quinone reductase and/or CYP reductase can leave available higher levels of E 1 (E 2 )-3,4-Q that may react with DNA (FIG. 2) . We think that unbalanced estrogen homeostasis represents the critical factor in the initiation of cancer by estrogens.
The effects of some of these factors have already been observed in several animal models for estrogen carcinogenesis and in the human breast. Imbalances in estrogen homeostasis leading to substantial formation of GSH conjugates and depurinating DNA adducts have been seen in the kidney of male Syrian golden hamsters, 42 the prostate of Noble rats, 43 and the mammary gland of female estrogen receptor-␣ knockout ERKO)/Wnt-1 mice. 44 Relative imbalances in estrogen homeostasis were also observed in women with breast carcinoma. 45 Levels of 4-OHE 1 (E 2 ) (P < 0.01) and E 1 (E 2 )-Q-GSH conjugates (P < 0.003) appeared to be highly significant predictors of breast cancer. 45 Therefore, it appears that the oxidative stress that leads to the formation of semiquinones and quinones of catechol estrogens is the result of unbalancing one or more factors in estrogen homeostasis.
MUTAGENICITY OF ESTROGENS
4-OHE 2 and E 2 -3,4-Q have been found to be mutagenic both in vitro and in vivo under appropriate assay conditions. The Big Blue embryonic rat2 cell line was used to detect mutagenesis in vitro. When these cells were treated six times with 200 nM 4-OHE 2 , the increase in mutant fraction (number of mutants/10 5 plaque-forming units) compared to untreated controls was statistically significant. 27 The major difference in the mutational spectra from the 4-OHE 2 -treated cells and untreated control cells was a higher percentage of mutations at A:T base pairs in the treated cells than in the controls (ca. 24% vs. 6%). This is the first demonstration of mutagenic activity by 4-OHE 2 . E 2 -3,4-Q has been shown to induce mutations in the skin of SENCAR mice 26 and the mammary gland of ACI rats (TABLE 1) . 28 Although equal amounts of 4-OHE 2 -1-N3Ade and 4-OHE 2 -1-N7Gua adducts were formed in both models, the vast majority of mutations were A:T to G:C transitions. These results suggest that the rapid depurination of the N3Ade adducts and slower depurination of the N7Gua adducts result predominantly in mutations at A:T base pairs. The rapid appearance of mutations in 6-12 h (TABLE 1) is consistent only with the mutations arising via error-prone base excision repair of the apurinic sites generated by the loss of the depurinating adducts. 25, 26, 28 In summary, the estrogen metabolites 4-OHE 2 and E 2 -3,4-Q have been shown to be mutagenic in cultured cells and in two animal models. [26] [27] [28] The pattern of mutations and their rapid appearance in vivo indicate that the mutations arise by error-prone base excision repair of the apurinic sites generated by the loss of 4-OHE 2 -1-N3Ade adducts.
UNIFYING MECHANISM OF TUMOR INITIATION BY NATURAL AND SYNTHETIC ESTROGENS
Oxidation of catechol estrogens to semiquinones and quinones is a pathway that can initiate cancer by endogenous estrogens, as well as synthetic estrogens such as the human carcinogen, diethylstilbestrol (DES) 46 and its hydrogenated derivative, hexestrol (HES). These compounds, similar to the natural estrogens, are carcinogenic in the kidney of Syrian golden hamsters; 1,47 the major metabolites are their catechols. [47] [48] [49] [50] These catechols are easily oxidized to catechol quinones. The catechol quinone of HES has chemical and biochemical properties similar to those of E 1 (E 2 )-3,4-Q; namely, it forms N3Ade and N7Gua adducts after reaction with DNA (FIG. 4) , and the depurination of the N7Gua adduct occurs rather slowly, analogously to the respective adducts of the natural E 1 (E 2 )-3,4-Q. [51] [52] [53] As expected, the catechol of DES, when oxidized to its quinone in the presence of DNA, produces the depurinating 3 -OHDES-6 -N3Ade and 3 -OHDES-6 -N7Gua adducts (FIG. 4) . 54 Therefore, the catechol quinones of HES and DES appear to be the critical initiators of cancer by these synthetic estrogens. In turn, these results support the hypothesis that E 1 (E 2 )-3,4-Q may be endogenous tumor initiators because they react with DNA to form specifically N3Ade and N7Gua adducts. In summary, the catechol quinones of natural and synthetic estrogens can be initiators of a variety of human cancers, including those of breast and prostate.
UNIFYING MECHANISM OF INITIATION OF CANCER AND OTHER DISEASES BY CATECHOL QUINONES
Oxidation of catechols to semiquinones and quinones is not only a mechanism of tumor initiation for natural and synthetic estrogens, but could also be the mechanism of tumor initiation for the leukemogen benzene. It has long been known that benzene causes acute myelogenous leukemia in humans. [55] [56] [57] Metabolites of benzene include catechol (1,2-dihydroxybenzene, CAT) and hydroquinone (1,4-dihydroxybenzene). [58] [59] [60] CAT and hydroquinone can accumulate in bone marrow, 61, 62 where they can be oxidized by peroxidases, including myeloperoxidase and prostaglandin H synthase. 63 The resulting CAT quinone can yield DNA adducts. In fact, oxidation of CAT by horseradish peroxidase, tyrosinase, or phenobarbital-induced rat liver microsomes in the presence of DNA yields the CAT-4-N7Gua adduct, while the CAT-4-N3Ade is obtained only with tyrosinase (FIG. 4) . 64 Thus, formation of depurinating adducts specifically at the N-7 position of Gua and N-3 position of Ade by 1,4-Michael addition of benzene-1,2-quinone to DNA and the slow depurination of the N7Gua adduct 65 suggest that oxidation of the metabolite CAT may play a major role in tumor initiation by benzene.
Inhalation of naphthalene has been found to induce olfactory epithelial neuroblastomas in 5-10% of male and female rats chronically exposed to naphthalene for 2 years. 66 The only logical mechanism of activation of naphthalene is analogous to the one described above for natural and synthetic estrogens and benzene. In fact, naphthalene-1,2-quinone reacts with DNA to form analogous depurinating N3Ade and N7Gua adducts (FIG. 4) . 67 The catecholamine neurotransmitter dopamine produces semiquinones and quinones via metal ion oxidation, peroxidative enzyme, or CYP oxidation. [68] [69] [70] The oxidative process is similar to the one described above for the benzene metabolite CAT and the catechols of naphthalene and the natural and synthetic estrogens. In fact, reaction of dopamine quinone with DNA forms depurinating N7Gua and N3Ade adducts (FIG. 4) . 64 The same adducts are obtained by enzymatic oxidation of dopamine in the presence of DNA. 64 Once again, the N7Gua depurinates slowly compared to the N3Ade adduct. 71 The mutations generated by this DNA damage may be at the origin of Parkinson's and other neurodegenerative diseases.
In conclusion, the catechol quinones of natural and synthetic estrogens, benzene, naphthalene, and dopamine can react with DNA to form specific depurinating adducts bonded at the N-7 of Gua or N-3 of Ade. The apurinic sites formed by these adducts, particularly the N3Ade adducts, may be converted by error-prone base excision repair into mutations that can initiate cancer and neurodegenerative diseases. This proposed unifying mechanism of the initiation of these diseases lays the groundwork for strategies to assess risk and prevent disease.
BIOMARKERS OF SUSCEPTIBILITY TO BREAST AND PROSTATE CANCER
We have hypothesized that the reaction of catechol estrogen quinones, in particular E 1 (E 2 )-3,4-Q, with DNA to form specific adducts is the first critical step in the process leading to cancer initiation. This suggests that imbalances in estrogen homeostasis result in higher levels of these adducts being formed in tissues in which cancer initiates. Since these adducts depurinate from DNA, they migrate from the cells and can be expected to be in body fluids and to serve as biomarkers of cancer risk.
We have determined the levels of adducts in urine from men with and without prostate cancer. 24 In this study, the 4-OHE 1 (E 2 )-1-N3Ade adduct was partially purified from urine and concentrated by using immuno-affinity chromatography with a monoclonal antibody specific for this adduct. The partially purified adduct was then identified and quantified by three different analytical methods: capillary electrophoresis with field-amplified sample stacking (CE-FASS), low-temperature phosphorescence (LTP), and ultraperformance liquid chromatography/tandem mass spectrometry (LC/MS/MS) (FIG. 5) . The samples from men with prostate cancer or other urological conditions contained higher levels of 4-OHE 1 (E 2 )-1-N3Ade adduct (10-240 pmol/mg creatinine) compared to the samples from healthy control men (background levels). These results provide initial evidence that the N3Ade adduct is a potential biomarker for prostate cancer.
We have begun a similar study of the level of adducts in urine from women with and without breast cancer. In this study, the levels of both 4-OHE 1 (E 2 )-1-N3Ade and 4-OHE 1 (E 2 )-1-N7Gua adducts, as well as 30 estrogen metabolites and conjugates, are detected by LC/MS/MS (TABLE 2), after solid-phase extraction of the estrogen compounds from 2-mL aliquots of urine. The sum of the N3Ade and N7Gua adducts in women with breast cancer ranged from 49 to 822, whereas the sum of the adducts in urine from healthy control women was less than 4. These results provide initial evidence that the N3Ade and N7Gua adducts can serve as potential biomarkers for breast cancer. 
CONCLUSIONS
We have acquired evidence for a unifying mechanism of initiation of cancer and other diseases. This mechanism predominantly entails formation of endogenous catechol estrogen-3,4-quinones that can react with DNA and yield depurinating adducts. E 2 -3,4-Q induces depurinating adducts in mouse skin and rat mammary gland that generate apurinic sites in the DNA. The fastdepurinating N3Ade adducts induce DNA lesions that are important for mutagenesis. In fact, a majority of mutations in the reporter Harvey-ras gene are A.T to G.C transitions. Similar A.T to G.C mutations are observed in the lacI reporter gene in Big Blue embryonic rat2 cells. Such mutations are thought to be critical in leading to the initiation of cancer.
The human carcinogen DES-3 ,4 -quinone, its hydrogenated derivative HES-3 ,4 -quinone, the catechol quinone of benzene, the naphthalene-1,2-quinone, and dopamine quinone react with DNA to form N3Ade and N7Gua adducts analogous to those of the natural estrogen-3,4-quinones. In a further similarity, for all of these depurinating adducts, the Ade adducts depurinate quickly, whereas the N7Gua adducts depurinate with a half-life of a few hours. From these similarities, we foresee a common unifying mechanism of disease initiation by these compounds.
The higher levels of depurinating estrogen-DNA adducts observed in urine from subjects with breast or prostate cancer suggest that these adducts could serve as biomarkers of susceptibility that can potentially be used to monitor the risk of breast and prostate cancer. This unifying mechanism of cancer initiation provides knowledge of the factors involved in this first critical step. Furthermore, this mechanism of the origin of cancer and other diseases suggests preventive strategies based on the level of depurinating DNA adducts that constitute the first critical step in the initiation of disease.
